Borthakur et al. am j hematol. 2014

Author: tbtk

August undefined, 2024

WebJan 6, 2024 · Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we … WebBackground: Temporomandibular joint (TMJ) ankylosis causes distortion of the anatomy of the upper airway resulting in some form of airway obstruction.Aim: The aim of this study …

CyTOForum • View topic - 2024-Borthakur et al-Am J Hematol

WebMar 16, 2024 · Drug-induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia. Benjamin Gallo Marin, Thomas A. Ollila, Allison Robbins, Blake E. Brooks, Elnaz F. Firoz, Cathy M. Massoud. Pages: 697-699. First Published: 24 September 2024. Abstract. WebJul 28, 2024 · 2024-Borthakur et al-Am J Hematol "Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated … free svg files for water bottles

Diagnosis and treatment of autoimmune hemolytic anemia in …

WebMay 1, 2014 · EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) is a common laboratory phenomenon. Its prevalence is reported to vary between 0.1-2% among hospitalized patients [1–3] and 15-17% in outpatients evaluated for isolated thrombocytopenia [4, 5].In contrast to serious and potential life-threatening causes of … WebNov 29, 2024 · Am J Hematol. 2014;89(10):964-8. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Jr., Gandhi VV, Faderl S, et al. Treatment of core-binding-factor in acute … farragut high school marching band

Clinical use of FLT3 inhibitors in acute myeloid leukemia OTT

Tyrosine kinase inhibitor discontinuation in patients with …

WebMar 20, 2024 · Semin Hematol (2014) 51 (3) ... Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al.. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. ... Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al.. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med (2024) 380 ... WebAug 23, 2024 · Sickle cell disease is caused by a single point mutation (Glu6Val) that promotes polymerisation of haemoglobin S and sickling of erythrocytes. Inflammation, haemolysis, microvascular obstruction, and organ damage characterise the clinical expression of the disease. Environmental and genetic factors influence many … farragut high school logoWebJul 6, 2024 · Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy … free svg files for thanksgiving

"WebMar 18, 2016 · Corresponding Author. Gautam Borthakur MD. The University of Texas MD Anderson Cancer Center, Houston, Texas. Corresponding author: Gautam Borthakur, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030; Fax: … " - Borthakur et al. am j hematol. 2014

Borthakur et al. am j hematol. 2014

Correlation between hemoglobin concentration and hematocrit …

WebSep 16, 2024 · Twenty patients (12 males and 8 females) with a median age at CML diagnosis of 60 years (range 44–78) were included in the present study. Four patients received dasatinib as first TKI, while 16 started imatinib and then switched to dasatinib, three of them after second-line nilotinib, for resistance (n = 9) or intolerance (n = 7).Dasatinib … WebHemothorax and hematocele: unusual presentations of vitamin K deficiency bleeding disorder Indian J Pediatr. 2013 Jan;80(1):80-1. doi: 10.1007/s12098-012-0750-8. Epub …

Did you know?

WebAcute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to comorbidities, frailty, complex biology and resistance to chemotherapy. 1-3 Front-line venetoclax (VEN) with hypomethylating agents (HMA) (VEN+HMA) have shown good … WebTorre LA, Bray F, Ferlay J, et al. CA Cancer J CLIN 2015;65:87-108 (IARC GLOBOCAN database) 2012; ... Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia - an Asian Myeloma Network (AMN) study. Am J Hematol. 2014 ;89:751-6. Hong J and Lee JH. Recent advances in MM:a Korean Perspective. Korean Journal Int Med …

WebObjectives: To validate the use of changes in hematocrit as an indicator of blood loss in adult trauma patients receiving IV fluids and to identify parameters of hematocrit … WebMar 24, 2024 · Disease overview. Multiple myeloma accounts for approximately 10% of hematologic malignancies. Diagnosis. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE) namely CRAB (hyper c alcemia, r enal failure, a nemia, …

WebApr 11, 2024 · Jackson K, Mollee P, Morris K et al (2014) Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. ... Walter RB, Othus M, Borthakur G et al (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel … WebJul 21, 2014 · Am J Hematol. 2014 Oct; 89(10): 964–968. Published online 2014 Jul 21. doi: 10.1002/ajh.23795. PMCID: PMC4431614. NIHMSID: NIHMS637506. ... Borthakur …

WebMay 1, 2024 · (2014) S. Berentsen et al. ... G. Borthakur et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors ... Autoimmune hemolytic anemia. Am J Hematol. (2002) R.J. Sokol et al. Autoimmune haemolysis: an 18-year study of 865 cases referred …

WebThe most common grade 3 or 4 nonhematologic toxicities were elevations in bilirubin and transaminases, nausea, peripheral neuropathy, and hyperglycemia, which were … farragut high school tennisWebApr 12, 2024 · Zurück zum Zitat Borthakur G, Dawson MA, Stein EM et al (2016) A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. ... Zurück zum Zitat Freytes CO, Vesole DH, LeRademacher … farragut high school staff directoryWebThe antithrombotic drugs, including anticoagulants, antiplatelet agents, and fibrinolytics, are among the most frequently used drug therapies in the United States. These agents … free svg files for teacher appreciationWebJun 16, 2024 · Am J Hematol. 2014;89:964–8. ... Peng J, Zuo Z, Daver N, Borthakur G, et al. Comparison of multiparameter flow cytometry immunophenotypic analysis and … farragut high school sportsWebJul 2, 2014 · Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in … free svg files for thanksgiving for cricutWebJan 3, 2024 · Am J Hematol. 2015;90(12):1111–5. Article CAS Google Scholar Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. free svg files laceWebOhanian M, Kantarjian HM, Borthakur G, et al. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+AML. ... Am J Hematol. 2015;90(4) ... Journal of Clinical Oncology. 2014;32:7100. 48. Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic ... farragut high school staff